Understanding more about the molecular pathogenesis of leukemia

Scientists conducted genome research on B acute lymphoblastic leukemia (B-ALL) and gained significant progress, full analysing molecular pathogenesis of the disease and providing a new model for medical precision. Related study was recently published in the journal E biomedicine.

B-ALL is a common type of acute leukemia and more common in children. It accounts 20% of adult acute leukemia. Long-term survival of B-ALL among Chinese children reaches about 70%, but there are still 20% to 30% of treatment failure, and adult long-term survival rate is only about 20%.

The United Study Group first used international application of the full set of exons, whole genome and whole transcriptome sequencing to conduct panoramic analysis of the genome on 92 adults and 111 children with B-ALL. This study not only confirmed the known major genetic abnormalities of the disease but also found 105 reproducible gene sequence mutations and 29 fusion gene which were not previously reported.

Studies have shown that fusion genes associated with MEF2D and ZNF384 can block the differentiation of early B lymphocytes, and ZNF384 fusion gene can also induce acute leukemia in a mouse model. The study also found that compared to the condition of children that they have a higher rate of positive fusion gene and poor prognosis, the molecular markers of good prognosis is obviously less, and the number of mutations in the gene sequence is significantly more.

The study reveals the pathogenesis of B-ALL, improving existing molecular diagnostic and prognostic classification system and prompting the intervention strategies of regulatory pathway for the B-ALL of abnormity of each group. One of the authors, Chinese Academy of Engineering academician Chen Saijuan said that the research result show direct application conversion prospects. Or the B-ALL precise classification model can be promoted to other leukemia and solid tumors, promoting the development of Chinese and international translational medicine and precision medicine.

Read more: http://www.cusabio.com/ELISA-Kit/Bovine-Japanese-Encephalitis-AntibodyIgGELISA-Kit-1042169.html